港通医疗
(301515)
| 流通市值：14.66亿 | | | 总市值：23.26亿 |
| 流通股本：6304.16万 | | | 总股本：1.00亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 344,363,431.23 | 265,246,991.85 | 24,286,732.74 | 754,058,316.42 |
| 营业收入 | 344,363,431.23 | 265,246,991.85 | 24,286,732.74 | 754,058,316.42 |
| 二、营业总成本 | 342,076,025.87 | 258,173,556.45 | 33,730,745.31 | 701,180,141.37 |
| 营业成本 | 267,049,285.19 | 206,648,422.61 | 15,507,795.01 | 604,228,113.76 |
| 税金及附加 | 3,692,053.17 | 2,683,194.45 | 882,604.66 | 5,201,822.9 |
| 销售费用 | 29,855,978.36 | 20,990,861.34 | 7,380,721.28 | 39,985,388.19 |
| 管理费用 | 26,554,651.14 | 17,660,531.42 | 6,194,321.4 | 31,796,379.32 |
| 研发费用 | 14,381,647.71 | 9,908,545.53 | 4,280,463.49 | 24,245,229.96 |
| 财务费用 | 542,410.3 | 282,001.1 | -515,160.53 | -4,276,792.76 |
| 其中:利息费用 | 4,771,565.03 | 3,103,833.89 | 1,605,605.99 | 6,314,008.83 |
| 其中:利息收入 | 4,579,309.09 | 3,201,679.11 | 2,162,019.44 | 11,244,971.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 511,856.85 | 511,856.85 | - | 957,316.41 |
| 加:投资收益 | -179,385.42 | -46,749.16 | - | - |
| 资产处置收益 | 114,157.19 | 114,157.19 | - | 75,411.84 |
| 资产减值损失(新) | -1,614,316.75 | -1,525,575.51 | -120,228.6 | -643,638.58 |
| 信用减值损失(新) | -19,080,939.17 | -19,743,183.35 | 10,872,919.37 | -47,778,144.26 |
| 其他收益 | 2,219,863.32 | 1,340,034.61 | 230,194.1 | 7,843,434.68 |
| 四、营业利润 | -15,741,358.62 | -12,276,023.97 | 1,538,872.3 | 13,332,555.14 |
| 加:营业外收入 | 404,915.31 | 347,786.33 | 18,237.59 | 2,066,516.09 |
| 减:营业外支出 | 116,484.05 | 111,641.17 | 52,437.67 | 298,270.94 |
| 五、利润总额 | -15,452,927.36 | -12,039,878.81 | 1,504,672.22 | 15,100,800.29 |
| 减:所得税费用 | -3,616,309.55 | -2,898,420.2 | -74,280.4 | 678,933.85 |
| 六、净利润 | -11,836,617.81 | -9,141,458.61 | 1,578,952.62 | 14,421,866.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -11,836,617.81 | -9,141,458.61 | 1,578,952.62 | 14,421,866.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -10,208,398.36 | -8,404,410.35 | 1,578,952.62 | 14,421,866.44 |
| 少数股东损益 | -1,628,219.45 | -737,048.26 | - | - |
| 扣除非经常损益后的净利润 | -12,865,150.31 | -10,269,336.53 | 1,414,324.12 | 5,008,448.99 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.11 | -0.09 | 0.02 | 0.15 |
| (二)稀释每股收益 | -0.11 | -0.09 | 0.02 | 0.15 |
| 八、其他综合收益 | -97,891.78 | -114,944.65 | - | -127,348.69 |
| 归属于母公司股东的其他综合收益 | -97,891.78 | -114,944.65 | - | -127,348.69 |
| 九、综合收益总额 | -11,934,509.59 | -9,256,403.26 | 1,578,952.62 | 14,294,517.75 |
| 归属于母公司股东的综合收益总额 | -10,306,290.14 | -8,519,355 | 1,578,952.62 | 14,294,517.75 |
| 归属于少数股东的综合收益总额 | -1,628,219.45 | -737,048.26 | - | - |
| 公告日期 | 2025-10-30 | 2025-08-29 | 2025-04-21 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |